Cargando…
Rapamycin-independent IGF2 expression in Tsc2-null mouse embryo fibroblasts and human lymphangioleiomyomatosis cells
Lymphangioleiomyomatosis (LAM) is a rare, almost exclusively female lung disease linked to inactivating mutations in tuberous sclerosis complex 2 (TSC2), a tumor suppressor gene that controls cell metabolic state and growth via regulation of the mechanistic target of rapamycin (mTORC1) signaling. mT...
Autores principales: | Himes, Blanca E., Obraztsova, Kseniya, Lian, Lurong, Shumyatcher, Maya, Rue, Ryan, Atochina-Vasserman, Elena N., Hur, Stella K., Bartolomei, Marisa S., Evans, Jilly F., Krymskaya, Vera P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5951544/ https://www.ncbi.nlm.nih.gov/pubmed/29758070 http://dx.doi.org/10.1371/journal.pone.0197105 |
Ejemplares similares
-
Inhibition of Growth of TSC2-Null Cells by a PI3K/mTOR Inhibitor but Not by a Selective MNK1/2 Inhibitor
por: Evans, Jilly F., et al.
Publicado: (2019) -
CrossTORC and WNTegration in Disease: Focus on Lymphangioleiomyomatosis
por: Evans, Jilly Frances, et al.
Publicado: (2021) -
Syndecan-2: Old Player in a New Field
por: Obraztsova, Kseniya, et al.
Publicado: (2019) -
MicroRNA-21 is Induced by Rapamycin in a Model of Tuberous Sclerosis (TSC) and Lymphangioleiomyomatosis (LAM)
por: Trindade, Anil J., et al.
Publicado: (2013) -
Lost in translation: a neglected mTOR target for lymphangioleiomyomatosis
por: Evans, Jilly F., et al.
Publicado: (2023)